AstraZeneca still well-placed after early vaccine results

20 July 2020

There was nothing to deter investors, governments and populations in a set of interim results from the ongoing Phase I/II COV001 trial of AZD1222, a COVID-19 vaccine candidate being developed by AstraZeneca (LSE: AZN) and the University of Oxford.

The vaccine was tolerated and generated robust immune responses against the SARS-CoV-2 virus in all evaluated participants in the COV001 trial, involving 1,077 healthy adult participants, aged 18 to 55 years.

Immune response and satisfactory safety

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK